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Background. To report on the activity of high-dose prolonged-infusion ifosfamide (HDIFX) chemotherapy in a retrospective series
of patients affected by myxoid liposarcoma treated at Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy. Patients and
Methods. Patients with an advanced myxoid liposarcoma treated with HDIFX (14 g/sqm, i.v., prolonged infusion of 14 days every
28 days) as a single agent between May 2002 and April 2017 were retrospectively reviewed. All pathologic diagnoses were centrally
reviewed and molecularly confirmed. Response was evaluated by RECIST, and survival functions were computed by the Kaplan-
Meier method. Results. Eleven patients with advanced myxoid liposarcoma were treated with HDIFX (male/female = 9/2, median
age 33 years, range 31–75). Among these, 1/11 received HDIFX in first line, 5/11 in second line, 3/11 in third line, and 2/11 in fourth
line for a median course number of 3 (range 2–7). No RECIST objective responses were observed. Overall median progression-free
survival was 1,9months.Median overall survival was 37months. At amedian follow-up of 115months, 1 patient is alive.Conclusions.
In this series of patients affected by advanced myxoid liposarcoma, chemotherapy with HDIFX was essentially inactive.
1. Introduction
Liposarcoma is the most common histological subtype
among soft tissue sarcomas. Specifically, myxoid/round cell
liposarcoma is the second of the three liposarcoma subtypes,
accounting for 30% of liposarcoma cases. Myxoid/round cell
liposarcoma typically occurs around the fifth decade (range
26–81 years) at any site of the body, mainly in the lower
extremities [1–4].
The diagnosis is supported by the detection of the
characteristic chromosomal recurrent translocation, namely,
t(12; 16)(q13; p11), which results in the aberrant fusion gene
FUS-CHOP/DDIT3 [5]. According to the most recent WHO
classification, myxoid liposarcomas can be morphologically
divided into high and low grade [3]. Standard treatment for
localized disease is surgery alone or in combination with
radiotherapy, while medical treatment may be offered in
selected cases and is often the main choice in the advanced
setting [6–9]. Myxoid liposarcomas are known as being
particularly sensitive to chemotherapy compared with other
soft tissue sarcomas [8–10], in particular to anthracycline-
based combinations and trabectedin. In the whole group
of advanced soft tissue sarcomas, first-line combination of
anthracycline and ifosfamide provides response rates around
20–40%. It increases to 65% inmyxoid liposarcoma [8, 11, 12].
On the other side, the expected response rate of myxoid
liposarcoma to trabectedin is 50% [13–18], with a mechanism
of action which is apparently specific inasmuch as implying
an effect of the drug on the binding of the fusion transcript to
target genes [16–18]. Recently, another marine-derived drug,
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eribulin, was shown to be effective in metastatic adipocytic
sarcomas, with a significant improvement in overall survival
which led to its approval by FDA and EMA [19–21]. However,
its activity in myxoid liposarcoma compared to pleomorphic
and well-differentiated/dedifferentiated liposarcoma is still
not defined. No other agents commonly used for treatment of
advanced soft tissue sarcoma (e.g., gemcitabine, dacarbazine,
and pazopanib) have been demonstrated to be active in
myxoid liposarcoma [2].
High-dose prolonged-infusion ifosfamide (HDIFX) is
known to be active in soft tissue sarcoma patients, even
in those previously treated with standard-dose ifosfamide
[2, 22–24]. A peculiar activity has been demonstrated in ded-
ifferentiated liposarcoma, especially with a high malignancy
grade component [10]. By contrast, no data are reported
so far on the activity of high-dose ifosfamide in myxoid
liposarcoma and no prospective neither retrospective studies
focusing on this drug in the disease are available.
The aim of this retrospective analysis was to review all
patients affected by advanced myxoid liposarcoma treated
with high-dose prolonged-infusion ifosfamide at our Institu-
tion.
2. Materials and Methods
All patients affected by advanced myxoid liposarcoma,
consecutively treated with HDIFX chemotherapy between
May 2002 and April 2017 at Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan, Italy, were retrospectively
identified. Pathological diagnosis was centrally reviewed by
expert pathologists in all the cases, following the most recent
updated criteria. Data regarding clinical and histopatho-
logical characteristics, staging, surgical and systemic treat-
ment, and survival were collected. The clinical records were
reviewed and collected in one institutional database and a
descriptive analysis was performed.
High-dose ifosfamide was administered as a single agent,
at the daily dose of 1 g/sqm (total dose of 14 g/sqm per
cycle), as a 14-day continuous infusion with the same dose
of MESNA every 4 weeks, through external portable infu-
sion devices (elastomeric pumps) each providing a 7-day
infusion, so that 2 pumps were used in each cycle. The
infusion was stopped with no additional MESNA after day
14. No additional hydration was foreseen and only oral
hydration with 1.5 L/day was recommended. When required,
antiemetic prophylaxis was based on oral ondansetron, or
dexamethasone, or metoclopramide. No granulocyte growth
factors were administered.The treatment was continued until
disease progression, serious adverse events, medical decision,
or patient refusal. Data on chemotherapy tolerability and
adverse effects were reviewed.
Treatment follow-up investigations included a whole-
body computed tomography scan (CT), amagnetic resonance
(MRI), or a CT of the primary site at baseline and then were
generally repeated after the first two courses of chemotherapy
and then every 2-3 months. Response Evaluation Criteria in
Solid Tumours (RECIST) were used to assess response to
chemotherapy [25].
This retrospective analysis was approved by the Institu-
tional Ethics Committee.
2.1. Statistical Analysis. Progression-free survival (PFS) and
overall survival (OS) were estimated with Kaplan-Meier
method [26]. Progression-free survival death and progressive
disease according to RECIST were considered as failures, and
death due to any cause was failure for OS. Patients alive were
censored at the time of the last contact.
3. Results
Within the study period, 11 patients affected by advanced
myxoid liposarcoma treated with HDIFX were identified.
Patient characteristics are summarized in Table 1. Male
patients were prevalent (male/female 9/2); median age at the
time of the treatmentwas 33 (range 31–75).Median number of
ifosfamide cycles per patient was 3 (range 2–7). Among these,
1/11 received HDIFX in first line, 5/11 in second line, 3/11 in
third line, and 2/11 in fourth line.
All patients had previously been treated with anthracy-
cline ± ifosfamide in adjuvant or advanced setting. Among
these, 7/11 patients were treated with epirubicin plus ifos-
famide in the adjuvant setting and 4/11 as first-line treatment
for advanced disease with 1/4 complete response (CR), 2/4
for partial response (PR), and 1/4 for stable disease (SD). In
the latter, median progression-free survival was 16.5 months
(range 6–21), with the only patient with SD experiencing a
PFS shorter than 1 year. Three/11 patients were pretreated
with trabectedin as well, with 2 PR and 1 SD. All patients
had metastatic disease when starting HDIFX, with a median
of 2 sites involved (range: 1–3); among these, the lung was
the most common involved site (8/11, 73%), followed by the
abdominal cavity (7/11, 64%), the bone (1/11, 9%), and the soft
tissues (1/11, 9%). Four patients (36%) had, in addition, a local
relapse.
All patients treated with HDIFX were evaluable for
response. The best response was PD in 7/11 (36%) and SD
in 4/11 (14%) with no PR or CR (Figure 1). Treatment was
withdrawn because of progressive disease in all cases. No
febrile neutropenia and renal failure were observed, as well
as no toxic deaths or any other unexpected serious adverse
events.
After a median follow-up of 115 months, OS was 37
months (Figure 2), with 10 patients dead and 1 patient alive
at the time of this analysis. Median PFS was 1,9 months
(Figure 3).
4. Discussion
In this small retrospective case-series of 11 patients with
progressing advanced myxoid liposarcoma treated with
chemotherapy on a 14-year span, no responses to continuous
infusion high-dose ifosfamide were observed. Median PFS
was 1,9 months, while median OS was 37 months.
Front-line ifosfamide combined with anthracyclines is
clinically active in adult advanced soft tissue sarcomas,
including liposarcomas [11, 12]. Following a histology-driven
Sarcoma 3
Figure 1: Multidetector computed tomography (MDCT) scan after contrast medium (arterial phase). Progression of abdominal metastasis
from a myxoid liposarcoma after two cycles of high-dose prolonged-infusion ifosfamide.
Table 1: Patients characteristics at chemotherapy when starting
ifosfamide.
Patients characteristics
Age, years
Median 33
Range 31–75
Histopathological diagnosis
Round cell myxoid liposarcoma (high grade) 7 (63%)
Classical myxoid liposarcoma (low grade) 4 (37%)
Metastatic disease at diagnosis 2 (18%)
Localized disease at diagnosis 9 (82%)
Adjuvant chemotherapy
Y 8 (73%)
N 3 (27%)
Adjuvant radiotherapy
Y 7 (64%)
N 4 (36%)
Number of sites involved
Median 2
Range 1–3
Local relapse 4 (36%)
Metastatic sites
Lung 8 (73%)
Abdominal cavity 7 (64%)
Bone 1 (9%)
Soft Tissue 1 (9%)
Number of prior chemotherapy regimens
0 1 (10%)
1 5 (45%)
2 3 (27%)
3 2 (18%)
Prior chemotherapy
Anthracycline ± Ifosfamide 11 (100%)
Trabectedin 3 (27%)
Pemetrexed 1 (10%)
Liposomal doxorubicin 1 (9%)
Unknown 2 (18%)
High-dose ifosfamide infusion
Elastomeric pump 11 (100%)
Number of ifosfamide courses
Median 3
Range (2–7)
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Figure 2: Overall survival (OS) of patients treated with high-dose
prolonged-infusion ifosfamide chemotherapy (11 patients). Median
OS was 37 months.
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Figure 3: Overall progression-free survival (PFS) of patients treated
with high-dose prolonged-infusion ifosfamide chemotherapy (11
patients). Median PFS was 1.9 months.
approach, high-dose ifosfamide as a single agent is often used
as second-/further line treatment, even in patients previously
treated with standard-dose ifosfamide.
HDIFX is known to be active in dedifferentiated liposar-
coma and other histotypes [2, 10, 22–24, 27]. In our series, all
patients had responded to anthracycline ± ifosfamide used
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as front-line treatment. These data are in line with studies
pointing to a high sensitivity to cytotoxic chemotherapy
of myxoid/round cell liposarcoma [8–10]. This is striking
if compared to the apparent lack of activity of HDIFX
in myxoid liposarcoma. Interestingly, there are no studies
comparing the activity of anthracycline plus ifosfamide
versus anthracycline alone in myxoid liposarcoma. On this
basis, it is not known to which extent ifosfamide adds to
anthracycline as a single agent in the first-line treatment of
myxoid liposarcoma. The fact that in our series HDIFX did
not show any antitumor activity raises doubts over its efficacy
in myxoid liposarcomas. Clearly, all patients included in this
series had been pretreated with doxorubicin plus ifosfamide,
and we cannot rule out that this was an acquired resistance to
the drug. However, the antitumor effect of ifosfamide as such
may be better evaluated prospectively also in first line.
5. Conclusions
This was a retrospective analysis; the number of patients
was limited and data refer to a 14-year span. However, it is
difficult to extrapolate evidence pertaining to this subgroup
of patients, let alone the lack of published retrospective
and prospective studies on HDIFX selectively in myxoid
liposarcoma. Thus, we believe that this series may stimulate
collection of further cases. It is unfortunate that even if
myxoid liposarcoma is considered chemosensitive among
soft tissue sarcomas, only anthracyclines and trabectedin are
active agents in this subtype at the moment. New medical
treatments would be definitely needed.
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